Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Pediatr Blood Cancer ; 71(7): e31041, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38715224

RESUMO

International and national oncofertility networks, including the US-led Oncofertility Consortium, FertiProtekt, and the Danish Network, have played pivotal roles in advancing the discipline of oncofertility over the last decade. Many other countries lack a shared approach to pediatric oncofertility health service delivery. This study aims to describe baseline oncofertility practices at Australian New Zealand Children's Haematology/Oncology Group centers in 2019-2021, describe binational priorities for care, and propose a 5-year action plan for best practice to be implemented by the newly formed Australian New Zealand Consortium in Children, Adolescents, and Young Adults (CAYA) Oncofertility (ANZCO).


Assuntos
Preservação da Fertilidade , Neoplasias , Humanos , Adolescente , Nova Zelândia , Preservação da Fertilidade/métodos , Criança , Neoplasias/terapia , Neoplasias/complicações , Adulto Jovem , Feminino , Austrália , Masculino , Adulto
2.
Clin Transl Sci ; 17(6): e13827, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38924306

RESUMO

For the same age, sex, and dosage, there can be significant variation in fertility outcomes in childhood cancer survivors. Genetics may explain this variation. This study aims to: (i) review the genetic contributions to infertility, (ii) search for pharmacogenomic studies looking at interactions of cancer treatment, genetic predisposition and fertility-related outcomes. Systematic searches in MEDLINE Ovid, Embase Classic+Embase, and PubMed were conducted using the following selection criteria: (i) pediatric, adolescent, and young adult cancer survivors, below 25 years old at the time of diagnosis, (ii) fertility outcome measures after cancer therapy, (iii) genetic considerations. Studies were excluded if they were (i) conducted in animal models, (ii) were not published in English, (iii) editorial letters, (iv) theses. Articles were screened in Covidence by at least two independent reviewers, followed by data extraction and a risk of bias assessment using the Quality in Prognostic Studies tool. Eight articles were reviewed with a total of 29 genes. Outcome measures included sperm concentration, azoospermia, AMH levels, assessment of premature menopause, ever being pregnant or siring a pregnancy. Three studies included replication cohorts, which attempted replication of SNP findings for NPY2R, BRSK1, FANCI, CYP2C19, CYP3A4, and CYP2B6. Six studies were rated with a high risk of bias. Differing methods may explain a lack of replication, and small cohorts may have contributed to few significant findings. Larger, prospective longitudinal studies with an unbiased genome-wide focus will be important to replicate significant results, which can be applied clinically.


Assuntos
Sobreviventes de Câncer , Fertilidade , Neoplasias , Adolescente , Criança , Feminino , Humanos , Masculino , Adulto Jovem , Antineoplásicos/efeitos adversos , Sobreviventes de Câncer/estatística & dados numéricos , Fertilidade/genética , Fertilidade/efeitos dos fármacos , Infertilidade/genética , Infertilidade/etiologia , Infertilidade/terapia , Neoplasias/genética , Neoplasias/tratamento farmacológico , Farmacogenética , Testes Farmacogenômicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA